CLINICAL_TRIALS
trial_result
· 2018-03-14
Clinical Trial Update: A Study of Baricitinib (LY3009104) in Participants With Moderate-to-Severe Atopic Dermatitis [Phase 2]
Summary
Phase 2 trial update for baricitinib in moderate-to-severe atopic dermatitis completed with results posted in 2018.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Eli Lilly and Company | Conditions: Atopic Dermatitis | Phase 2 | Status: COMPLETED | Results posted: 2018-03-14